Meeting
2021 ASCO Annual Meeting
Association between improvements in survival of metastatic NSCLC patients and targeted- and immuno-therapy.
Authors
Sreeram Ramagopalan
F. Hoffmann-La Roche Ltd., Basel, Switzerland
Sreeram Ramagopalan , Thomas P. Leahy , Joshua Ray , Samantha Wilkinson , Cormac J. Sammon , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9090)
DOI
10.1200/JCO.2021.39.15_suppl.9090
Abstract #
9090
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation.
First Author: Laura Carter
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and feasibility of immuno-cryotherapy.
First Author: Junaid Raja
Poster
2017 ASCO Annual Meeting
Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.
First Author: Luis G. Paz-Ares
Poster
2024 ASCO Annual Meeting
Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis.
First Author: Vivek Podder